SCHEMBL18340816

SCHEMBL18340816

COC(=O)c1ccc(Br)c(NC(=S)NC(=O)c2ccccc2)c1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.63
▸ MAPT P10636 5/20 0.63
▸ KMT2A Q03164 5/20 0.63
▸ KDM4E B2RXH2 3/20 0.63
▸ ALOX12 P18054 3/20 0.63
▸ MEN1 O00255 3/20 0.63
▸ HPGD P15428 1/20 0.63
▸ EPHX1 P07099 6/20 0.60
▸ HDAC1 Q13547 1/20 0.54
▸ HDAC8 Q9BY41 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ PLK1 P53350 1/20 0.54
▸ NPC1 O15118 4/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18340971 0.83 EPHX1 (0.65) ALDH1A1MAPTKDM4EALOX12EPHX1
SCHEMBL3662241 0.83 EPHX1 (0.67) ALDH1A1MAPTEPHX1HDAC1HDAC8
SCHEMBL23496704 0.81 EPHX1 (0.64) ALDH1A1MAPTKMT2AMEN1EPHX1
SCHEMBL30479195 0.81 EPHX1 (0.64) ALDH1A1MAPTKMT2AMEN1EPHX1
SCHEMBL24092944 0.81 EPHX1 (0.76) ALDH1A1MAPTKMT2AMEN1EPHX1
SCHEMBL3050543 0.80 EPHX1 (0.69) ALDH1A1MAPTKMT2AKDM4EALOX12
SCHEMBL14096335 0.79 RAB9A (0.77) ALDH1A1MAPTKMT2AKDM4EALOX12
SCHEMBL31398632 0.79 ALDH1A1 (0.77) ALDH1A1MAPTKMT2AKDM4EALOX12
SCHEMBL31394873 0.79 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1EPHX1PLK1
SCHEMBL18340856 0.79 ALDH1A1 (0.73) ALDH1A1KMT2AMEN1EPHX1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 — — EP disclosed
US-10227331-B2 Metallo-β-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-12 — — US disclosed
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS Marck Sharp & Dohme Corp. (US) 2018-06-28 — — US disclosed
EP-3313828-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-05-02 — — EP disclosed
WO-2016206101-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 — — WO disclosed
WO-2016210234-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227331-B2 Metallo-β-lactamase inhibitors ALPI, GAA, ZFX ALDH1A1 310/4885MAPT 3705/4885KMT2A 1166/4885
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS ALPI, GAA, ZFX ALDH1A1 319/4885MAPT 3748/4885KMT2A 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback